Elucidating GABAA and GABAB receptor functions in anxiety using the stress-induced hyperthermia paradigm: A review

Open Pharmacology Journal

Volumn 4, Issue 1, 2010, Pages 1-14

  Vinkers, Christiaan H ^a   Cryan, John F ^b   Olivier, Berend ^a,c   Groenink, Lucianne ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug screening; Emotional fever; Ionotropic; Model; Tp003; Tpa023; Zolpidem; Zopiclone

Indexed keywords

2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; ABECARNIL; ALCOHOL; ALPRAZOLAM; BACLOFEN; BENZODIAZEPINE; BICUCULLINE; BRETAZENIL; CHLORDIAZEPOXIDE; DIAZEPAM; ETOMIDATE; G PROTEIN COUPLED RECEPTOR; GABOXADOL; GLUTAMATE RECEPTOR; GLYCINE RECEPTOR; HYPNOTIC AGENT; INWARDLY RECTIFYING POTASSIUM CHANNEL; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID; NEUROSTEROID; NITRAZEPAM; OXAZEPAM; PHENOBARBITAL; PROPOFOL; RECEPTOR SUBTYPE; SEROTONIN RECEPTOR; UNINDEXED DRUG; ZOLPIDEM;

ANTICONVULSANT ACTIVITY; ANXIETY; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; CORE TEMPERATURE; DEPRESSION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; EMOTIONAL DISORDER; GABAERGIC SYSTEM; HUMAN; HYPERTHERMIA; HYPOTHERMIA; NONHUMAN; PHYSICAL STRESS; PRIORITY JOURNAL; RAT; REVIEW; SEDATION; SIDE EFFECT; STRESS; STRESS INDUCED HYPERTHERMIA; TRANQUILIZING ACTIVITY; VALIDITY;

EID: 80053160178     PISSN: None     EISSN: 18741436     Source Type: Journal    
DOI: 10.2174/1874143601004010001     Document Type: Review

References (112)

1. Vinkers, C.H.; van Bogaert, M.J.; Klanker, M.; Korte, S.M.; Oosting, R.; Hanania, T.; Hopkins, S.C.; Olivier, B.; Groenink, L. Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm. Eur. J. Pharmacol., 2008, 585, 407-425.
2. Renbourn, E.T. Body temperature and pulse rate in boys and young men prior to sporting contests. A study of emotional hyperthermia: with a review of the literature. J. Psychosom. Res., 1960, 4, 149-175.
3. Kleitman, N.; Jackson, D.P. Body temperature and performance under different routines. J. Appl. Physiol., 1950, 3, 309-328.
4. Borsini, F.; Lecci, A.; Volterra, G.; Meli, A. A model to measure anticipatory anxiety in mice? Psychopharmacology (Berl), 1989, 98, 207-211.
5. Zethof, T.J.; Van der Heyden, J.A.; Tolboom, J.T.; Olivier, B. Stress-induced hyperthermia as a putative anxiety model. Eur. J. Pharmacol., 1995, 294, 125-135.
6. Vinkers, C.H.; Klanker, M.; Groenink, L.; Korte, S.M.; Cook, J.M.; Van Linn, M.L.; Hopkins, S.C.; Olivier, B. Dissociating anxiolytic and sedative effects of GABAAergic drugs using temperature and locomotor responses to acute stress. Psychopharmacology (Berl), 2009, 204, 299-311.
7. van Bogaert, M.J.; Groenink, L.; Oosting, R.S.; Westphal, K.G.; van der Gugten, J.; Olivier, B. Mouse strain differences in autonomic responses to stress. Genes Brain Behav., 2006, 5, 139-149.
8. Bouwknecht, J.A.; Olivier, B.; Paylor, R.E. The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse. Neurosci. Biobehav. Rev., 2007, 31, 41-59.
9. Pirker, S.; Schwarzer, C.; Wieselthaler, A.; Sieghart, W.; Sperk, G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience, 2000, 101, 815-850.
10. Castelli, M.P.; Ingianni, A.; Stefanini, E.; Gessa, G.L. Distribution of GABA(B) receptor mRNAs in the rat brain and peripheral organs. Life Sci., 1999, 64, 1321-1328.
11. Rudolph, U.; Mohler, H. GABA-based therapeutic approaches: GABAA receptor subtype functions. Curr. Opin. Pharmacol., 2006, 6, 18-23.
12. Cryan, J.F.; Holmes, A. The ascent of mouse: advances in modelling human depression and anxiety. Nat. Rev. Drug Discov., 2005, 4, 775-790.
13. Cryan, J.F.; Kelly, P.H.; Chaperon, F.; Gentsch, C.; Mombereau, C.; Lingenhoehl, K.; Froestl, W.; Bettler, B.; Kaupmann, K.; Spooren, W.P. Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J. Pharmacol. Exp. Ther., 2004, 310, 952-963.
14. Wisden, W.; Laurie, D.J.; Monyer, H.; Seeburg, P.H. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J. Neurosci., 1992, 12, 1040-1062.
15. Sibille, E.; Pavlides, C.; Benke, D.; Toth, M. Genetic inactivation of the Serotonin(1A) receptor in mice results in downregulation of major GABA(A) receptor alpha subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety. J. Neurosci., 2000, 20, 2758-2765.
16. Benke, D.; Fakitsas, P.; Roggenmoser, C.; Michel, C.; Rudolph, U.; Mohler, H. Analysis of the presence and abundance of GABAA receptors containing two different types of alpha subunits in murine brain using point-mutated alpha subunits. J. Biol. Chem., 2004, 279, 43654-43660.
17. Sieghart, W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol. Rev., 1995, 47, 181-234.
18. Rudolph, U.; Crestani, F.; Benke, D.; Brunig, I.; Benson, J.A.; Fritschy, J.M.; Martin, J.R.; Bluethmann, H.; Mohler, H. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature, 1999, 401, 796-800.
19. Crestani, F.; Low, K.; Keist, R.; Mandelli, M.; Mohler, H.; Rudolph, U. Molecular targets for the myorelaxant action of diazepam. Mol. Pharmacol., 2001, 59, 442-445.
20. Dias, R.; Sheppard, W.F.; Fradley, R.L.; Garrett, E.M.; Stanley, J.L.; Tye, S.J.; Goodacre, S.; Lincoln, R.J.; Cook, S.M.; Conley, R.; Hallett, D.; Humphries, A.C.; Thompson, S.A.; Wafford, K.A.; Street, L.J.; Castro, J.L.; Whiting, P.J.; Rosahl, T.W.; Atack, J.R.; McKernan, R.M.; Dawson, G.R.; Reynolds, D.S. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J. Neurosci., 2005, 25, 10682-10688.
21. McKernan, R.M.; Rosahl, T.W.; Reynolds, D.S.; Sur, C.; Wafford, K.A.; Atack, J.R.; Farrar, S.; Myers, J.; Cook, G.; Ferris, P.; Garrett, L.; Bristow, L.; Marshall, G.; Macaulay, A.; Brown, N.; Howell, O.; Moore, K.W.; Carling, R.W.; Street, L.J.; Castro, J.L.; Ragan, C.I.; Dawson, G.R.; Whiting, P.J. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat. Neurosci., 2000, 3, 587 592.
22. Low, K.; Crestani, F.; Keist, R.; Benke, D.; Brunig, I.; Benson, J.A.; Fritschy, J.M.; Rulicke, T.; Bluethmann, H.; Mohler, H.; Rudolph, U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science, 2000, 290, 131-134.
23. van Steveninck, A.L.; Gieschke, R.; Schoemaker, R.C.; Roncari, G.; Tuk, B.; Pieters, M.S.; Breimer, D.D.; Cohen, A.F. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br. J. Clin. Pharmacol., 1996, 41, 565 573.
24. Lippa, A.; Czobor, P.; Stark, J.; Beer, B.; Kostakis, E.; Gravielle, M.; Bandyopadhyay, S.; Russek, S.J.; Gibbs, T.T.; Farb, D.H.; Skolnick, P. Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc. Natl. Acad. Sci. USA, 2005, 102, 7380-7385.
25. Popik, P.; Kostakis, E.; Krawczyk, M.; Nowak, G.; Szewczyk, B.; Krieter, P.; Chen, Z.; Russek, S.J.; Gibbs, T.T.; Farb, D.H.; Skolnick, P.; Lippa, A.S.; Basile, A.S. The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)me th anone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors. J. Pharmacol. Exp. Ther., 2006, 319, 1244-1252.
26. Wafford, K.A.; Whiting, P.J.; Kemp, J.A. Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes. Mol. Pharmacol., 1993, 43, 240-244.
27. Graham, N.M.; Burrell, C.J.; Douglas, R.M.; Debelle, P.; Davies, L. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J. Infect. Dis., 1990, 162, 1277-1282.
28. Calver, A.R.; Davies, C.H.; Pangalos, M. GABA(B) receptors: from monogamy to promiscuity. Neurosignals, 2002, 11, 299-314.
29. Bettler, B.; Kaupmann, K.; Mosbacher, J.; Gassmann, M. Molecular structure and physiological functions of GABA(B) receptors. Physiol. Rev., 2004, 84, 835-867.
30. Cryan, J.F.; Kaupmann, K. Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol. Sci., 2005, 26, 36-43.
31. Drake, R.G.; Davis, L.L.; Cates, M.E.; Jewell, M.E.; Ambrose, S.M.; Lowe, J.S. Baclofen treatment for chronic posttraumatic stress disorder. Ann. Pharmacother., 2003, 37, 1177-1181.
32. Addolorato, G.; Caputo, F.; Capristo, E.; Domenicali, M.; Bernardi, M.; Janiri, L.; Agabio, R.; Colombo, G.; Gessa, G.L.; Gasbarrini, G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol, 2002, 37, 504-508.
33. Addolorato, G.; Leggio, L.; Abenavoli, L.; Agabio, R.; Caputo, F.; Capristo, E.; Colombo, G.; Gessa, G.L.; Gasbarrini, G. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am. J. Med., 2006, 119, 276 e13-18.
34. Breslow, M.F.; Fankhauser, M.P.; Potter, R.L.; Meredith, K.E.; Misiaszek, J.; Hope, D.G., Jr. Role of gamma-aminobutyric acid in antipanic drug efficacy. Am. J. Psychiatry, 1989, 146, 353-356.
35. Hinderer, S.R. The supraspinal anxiolytic effect of baclofen for spasticity reduction. Am. J. Phys. Med. Rehabil., 1990, 69, 254-258.
36. Nastiti, K.; Benton, D.; Brain, P.F. The effects of compounds acting at the benzodiazepine receptor complex on the ultrasonic calling of mouse pups. Behav. Pharmacol., 1991, 2, 121-128.
37. Shephard, R.A.; Wedlock, P.; Wilson, N.E. Direct evidence for mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol. Biochem. Behav., 1992, 41, 651-653.
38. Andrews, N.; File, S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol., 1993, 235, 109-112.
39. Dalvi, A.; Rodgers, R.J. GABAergic influences on plus-maze behaviour in mice. Psychopharmacology (Berl), 1996, 128, 380-397.
40. File, S.E.; Zharkovsky, A.; Gulati, K. Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat. Neuropharmacology, 1991, 30, 183-190.
41. File, S.E.; Mabbutt, P.S.; Andrews, N. Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen. Psychopharmacology (Berl), 1991, 104, 62-66.
42. File, S.E.; Andrews, N.; Wu, P.Y.; Zharkovsky, A.; Zangrossi, H., Jr. Modification of chlordiazepoxide's behavioural and neurochemical effects by handling and plus-maze experience. Eur. J. Pharmacol., 1992, 218, 9-14.
43. Mombereau, C.; Kaupmann, K.; Froestl, W.; Sansig, G.; van der Putten, H.; Cryan, J.F. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety and antidepressant-like behavior. Neuropsychopharmacology, 2004, 29, 1050-1062.
44. Mombereau, C.; Kaupmann, K.; Gassmann, M.; Bettler, B.; van der Putten, H.; Cryan, J.F. Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport, 2005, 16, 307-310.
45. Shaban, H.; Humeau, Y.; Herry, C.; Cassasus, G.; Shigemoto, R.; Ciocchi, S.; Barbieri, S.; van der Putten, H.; Kaupmann, K.; Bettler, B.; Luthi, A. Generalization of amygdala LTP and conditioned fear in the absence of presynaptic inhibition. Nat. Neurosci., 2006, 9(8), 1028-1035.
46. Jacobson, L.H.; Cryan, J.F. Differential sensitivity to the motor and hypothermic effects of the GABA B receptor agonist baclofen in various mouse strains. Psychopharmacology (Berl), 2005, 179, 688-699.
47. Urwyler, S.; Mosbacher, J.; Lingenhoehl, K.; Heid, J.; Hofstetter, K.; Froestl, W.; Bettler, B.; Kaupmann, K. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol. Pharmacol., 2001, 60, 963-971.
48. Urwyler, S.; Pozza, M.F.; Lingenhoehl, K.; Mosbacher, J.; Lampert, C.; Froestl, W.; Koller, M.; Kaupmann, K. N,N' Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J. Pharmacol. Exp. Ther., 2003, 307, 322-330.
49. Malherbe, P.; Masciadri, R.; Norcross, R.D.; Knoflach, F.; Kratzeisen, C.; Zenner, M.T.; Kolb, Y.; Marcuz, A.; Huwyler, J.; Nakagawa, T.; Porter, R.H.; Thomas, A.W.; Wettstein, J.G.; Sleight, A.J.; Spooren, W.; Prinssen, E.P. Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Br. J. Pharmacol., 2008, 154, 797-811.
50. Jacobson, L.H.; Guery, S.; Froestl, W.; Gentsch, C.; Enz, A.; Cryan, J.F.; Kaupmann, K. In vitro and in vivo characterization of a novel GABAB receptor positive allosteric modulator. Program No 824.5. Neuroscience meeting planner, Washington, DC, Society for Neuroscience 2008.
51. Paterson, N.E.; Vlachou, S.; Guery, S.; Kaupmann, K.; Froestl, W.; Markou, A. Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J. Pharmacol. Exp. Ther., 2008, 326, 306-314.
52. Dupuis, D.S.; Relkovic, D.; Lhuillier, L.; Mosbacher, J.; Kaupmann, K. Point mutations in the transmembrane region of GABAB2 facilitate activation by the positive modulator N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) in the absence of the GABAB1 subunit. Mol. Pharmacol., 2006, 70, 2027-2036.
53. Carai, M.A.; Colombo, G.; Froestl, W.; Gessa, G.L. In vivo effectiveness of CGP7930, a positive allosteric modulator of the GABAB receptor. Eur. J. Pharmacol., 2004, 504, 213-216.
54. Gjoni, T.; Desrayaud, S.; Imobersteg, S.; Urwyler, S. The positive allosteric modulator GS39783 enhances GABA(B) receptor- mediated inhibition of cyclic AMP formation in rat striatum in vivo. J. Neurochem., 2006, 96, 1416-1422.
55. Jacobson, L.H.; Cryan, J.F. Evaluation of the anxiolytic-like profile of the GABAB receptor positive modulator CGP7930 in rodents. Neuropharmacology, 2008, 54, 854-862.
56. Iijima, M.; Shimazaki, T.; Ito, A.; Chaki, S. Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice. Psychopharmacology (Berl), 2007, 190, 233-239.
57. Stemmelin, J.; Cohen, C.; Terranova, J.P.; Lopez-Grancha, M.; Pichat, P.; Bergis, O.; Decobert, M.; Santucci, V.; Francon, D.; Alonso, R.; Stahl, S.M.; Keane, P.; Avenet, P.; Scatton, B.; le Fur, G.; Griebel, G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology, 2008, 33, 574-587.
58. Nordquist, R.E.; Durkin, S.; Jaeschke, G.; Spooren, W. Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP. Eur. J. Pharmacol., 2007, 568, 199-202.
59. Pritchett, D.B.; Luddens, H.; Seeburg, P.H. Type I and type II GABAA-benzodiazepine receptors produced in transfected cells. Science, 1989, 245, 1389-1392.
60. Pritchett, D.B.; Seeburg, P.H. Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem., 1990, 54, 1802-1804.
61. Olivier, B.; Bouwknecht, J.A.; Pattij, T.; Leahy, C.; van Oorschot, R.; Zethof, T.J. GABAA-benzodiazepine receptor complex ligands and stress-induced hyperthermia in singly housed mice. Pharmacol. Biochem. Behav., 2002, 72, 179-188.
62. Pattij, T.; Groenink, L.; Oosting, R.S.; van der G.J.; Maes, R.A.; Olivier, B. GABA(A)-benzodiazepine receptor complex sensitivity in 5-HT(1A) receptor knockout mice on a 129/Sv background. Eur. J. Pharmacol., 2002, 447, 67-74.
63. Van Bogaert, M.; Oosting, R.; Toth, M.; Groenink, L.; van Oorschot, R.; Olivier, B. Effects of genetic background and null mutation of 5-HT1A receptors on basal and stress-induced body temperature: modulation by serotonergic and GABAA-ergic drugs. Eur. J. Pharmacol., 2006, 550, 84-90.
64. Ebert, B.; Wafford, K.A.; Deacon, S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol. Ther., 2006, 112, 612-629.
65. Vinkers, C.H.; Klanker, M.; Groenink, L.; Korte, S.M.; Cook, J.M.; Van Linn, M.L.; Hopkins, S.C.; Olivier, B. Dissociating anxiolytic and sedative effects of GABA(A)ergic drugs using temperature and locomotor responses to acute stress. Psychopharmacology (Berl), 2009.
66. Atack, J.R.; Smith, A.J.; Emms, F.; McKernan, R.M. Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for alpha 1 vs alpha 2 and alpha 3 subunit-containing GABAA receptors. Neuropsychopharmacology, 1999, 20, 255-262.
67. Collinson, N.; Kuenzi, F.M.; Jarolimek, W.; Maubach, K.A.; Cothliff, R.; Sur, C.; Smith, A.; Otu, F.M.; Howell, O.; Atack, J.R.; McKernan, R.M.; Seabrook, G.R.; Dawson, G.R.; Whiting, P.J.; Rosahl, T.W. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J. Neurosci., 2002, 22, 5572-5580.
68. Dawson, G.R.; Maubach, K.A.; Collinson, N.; Cobain, M.; Everitt, B.J.; MacLeod, A.M.; Choudhury, H.I.; McDonald, L.M.; Pillai, G.; Rycroft, W.; Smith, A.J.; Sternfeld, F.; Tattersall, F.D.; Wafford, K.A.; Reynolds, D.S.; Seabrook, G.R.; Atack, J.R. An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J. Pharmacol. Exp. Ther., 2006, 316, 1335-1345.
69. Potier, M.C.; Prado de Carvalho, L.; Venault, P.; Chapouthier, G.; Rossier, J. Demonstration of the partial agonist profiles of Ro 16-6028 and Ro 17-1812 in mice in vivo. Eur. J. Pharmacol., 1988, 156, 169-172.
70. Huang, Q.; He, X.; Ma, C.; Liu, R.; Yu, S.; Dayer, C.A.; Wenger, G.R.; McKernan, R.; Cook, J.M. Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach. J. Med. Chem., 2000, 43, 71-95.
71. Atack, J.R.; Hutson, P.H.; Collinson, N.; Marshall, G.; Bentley, G.; Moyes, C.; Cook, S.M.; Collins, I.; Wafford, K.; McKernan, R.M.; Dawson, G.R. Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. Br. J. Pharmacol., 2005, 144, 357-366.
72. File, S.E.; Baldwin, H.A. Effects of beta-carbolines in animal models of anxiety. Brain Res. Bull., 1987, 19, 293-299.
73. Hofmann, S.G.; Newman, M.G.; Ehlers, A.; Roth, W.T. Psychophysiological differences between subgroups of social phobia. J. Abnorm. Psychol., 1995, 104, 224-231.
74. Hoehn-Saric, R.; McLeod, D.R.; Funderburk, F.; Kowalski, P. Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder: an ambulatory monitor study. Arch. Gen. Psychiatry, 2004, 61, 913-921.
75. van der Wee, N.J.; Fiselier, J.; van Megen, H.J.; Westenberg, H.G. Behavioural effects of rapid intravenous administration of metachlorophenylpiperazine in patients with panic disorder and controls. Eur. Neuropsychopharmacol., 2004, 14, 413-417.
76. Van Veen, J.F.; Van der Wee, N.J.; Fiselier, J.; Van Vliet, I.M.; Westenberg, H.G. Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls. Eur. Neuropsychopharmacol., 2007, 17, 637-642.
77. Savic, M.M.; Obradovic, D.I.; Ugresic, N.D.; Cook, J.M.; Yin, W.; Van Linn, M.; Bokonjic, D.R. Benzodiazepine site inverse agonists and locomotor activity in rats: bimodal and biphasic influence. Pharmacol. Biochem. Behav., 2006, 84, 35-42.
78. Wallner, M.; Olsen, R.W. Physiology and pharmacology of alcohol: the imidazobenzodiazepine alcohol antagonist site on subtypes of GABAA receptors as an opportunity for drug development? Br. J. Pharmacol., 2008, 154, 288-298.
79. Jia, F.; Chandra, D.; Homanics, G.E.; Harrison, N.L. Ethanol modulates synaptic and extrasynaptic GABAA receptors in the thalamus. J. Pharmacol. Exp. Ther., 2008, 326, 475-482.
80. Roberto, M.; Madamba, S.G.; Moore, S.D.; Tallent, M.K.; Siggins, G.R. Ethanol increases GABAergic transmission at both preand postsynaptic sites in rat central amygdala neurons. Proc. Natl. Acad. Sci. USA, 2003, 100, 2053-2058.
81. Dopico, A.M.; Lovinger, D.M. Acute alcohol action and desensitization of ligand-gated ion channels. Pharmacol. Rev., 2009, 61, 98-114.
82. Harris, R.A. Ethanol actions on multiple ion channels: which are important? Alcohol Clin. Exp. Res., 1999, 23, 1563-1570.
83. Langen, B.; Dietze, S.; Fink, H. Acute effect of ethanol on anxiety and 5-HT in the prefrontal cortex of rats. Alcohol, 2002, 27, 135-141.
84. Mihalek, R.M.; Banerjee, P.K.; Korpi, E.R.; Quinlan, J.J.; Firestone, L.L.; Mi, Z.P.; Lagenaur, C.; Tretter, V.; Sieghart, W.; Anagnostaras, S.G.; Sage, J.R.; Fanselow, M.S.; Guidotti, A.; Spigelman, I.; Li, Z.; DeLorey, T.M.; Olsen, R.W.; Homanics, G.E. Attenuated sensitivity to neuroactive steroids in gamma aminobutyrate type A receptor delta subunit knockout mice. Proc. Natl. Acad. Sci. USA, 1999, 96, 12905-12910.
85. Lecci, A.; Borsini, F.; Volterra, G.; Meli, A. Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology (Berl), 1990, 101, 255-261.
86. Olivier, B.; Zethof, T.; Pattij, T.; van Boogaert, M.; van Oorschot, R.; Leahy, C.; Oosting, R.; Bouwknecht, A.; Veening, J.; van der Gugten, J.; Groenink, L. Stress-induced hyperthermia and anxiety: pharmacological validation. Eur. J. Pharmacol., 2003, 463, 117-132.
87. Rorick-Kehn, L.M.; Hart, J.C.; McKinzie, D.L. Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology (Berl), 2005, 183, 226-240.
88. Spooren, W.P.; Schoeffter, P.; Gasparini, F.; Kuhn, R.; Gentsch, C. Pharmacological and endocrinological characterisation of stress- induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol., 2002, 435, 161-170.
89. Chen, S.W.; Xin, Q.; Kong, W.X.; Min, L.; Li, J.F. Anxiolytic-like effect of succinic acid in mice. Life Sci., 2003, 73, 3257-3264.
90. Groenink, L.; van der G.J.; Zethof, T.J.; van der Heyden, J.A.; Olivier, B. Neuroendocrine effects of diazepam and flesinoxan in the stress-induced hyperthermia test in mice. Pharmacol. Biochem. Behav., 1996, 54, 249-254.
91. Pattij, T.; Hijzen, T.H.; Groenink, L.; Oosting, R.S.; van der Gugten, J.; Maes, R.A.; Hen, R.; Olivier, B. Stress-induced hyperthermia in the 5-HT(1A) receptor knockout mouse is normal. Biol. Psychiatry, 2001, 49, 569-574.
92. Satow, A.; Maehara, S.; Ise, S.; Hikichi, H.; Fukushima, M.; Suzuki, G.; Kimura, T.; Tanak, T.; Ito, S.; Kawamoto, H.; Ohta, H. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2- fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl- N-methyl-3,6-dihydropyridine-1(2H)-carboxamide]. J. Pharmacol. Exp. Ther., 2008, 326, 577-586.
93. Chen, S.W.; Min, L.; Li, W.J.; Kong, W.X.; Li, J.F.; Zhang, Y.J. The effects of angelica essential oil in three murine tests of anxiety. Pharmacol. Biochem. Behav., 2004, 79, 377-382.
94. Van der Heyden, J.A.; Zethof, T.J.; Olivier, B. Stress-induced hyperthermia in singly housed mice. Physiol. Behav., 1997, 62, 463-470.
95. Amin, J.; Weiss, D.S. GABAA receptor needs two homologous domains of the beta-subunit for activation by GABA but not by pentobarbital. Nature, 1993, 366, 565-569.
96. Boileau, A.J.; Evers, A.R.; Davis, A.F.; Czajkowski, C. Mapping the agonist binding site of the GABAA receptor: evidence for a beta-strand. J. Neurosci., 1999, 19, 4847-4854.
97. Ebert, B.; Wafford, K.A.; Whiting, P.J.; Krogsgaard-Larsen, P.; Kemp, J.A. Molecular pharmacology of gamma-aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different alpha, beta, and gamma receptor subunit combinations. Mol. Pharmacol., 1994, 46, 957-963.
98. Baumann, S.W.; Baur, R.; Sigel, E. Individual properties of the two functional agonist sites in GABA(A) receptors. J. Neurosci., 2003, 23, 11158-11166.
99. Wafford, K.A.; Ebert, B. Gaboxadol--a new awakening in sleep. Curr. Opin. Pharmacol., 2006, 6, 30-36.
100. Saarelainen, K.S.; Ranna, M.; Rabe, H.; Sinkkonen, S.T.; Moykkynen, T.; Uusi-Oukari, M.; Linden, A.M.; Luddens, H.; Korpi, E.R. Enhanced behavioral sensitivity to the competitive GABA agonist, gaboxadol, in transgenic mice over-expressing hippocampal extrasynaptic alpha6beta GABA(A) receptors. J. Neurochem., 2008, 105, 338-350.
101. Farrant, M.; Nusser, Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci., 2005, 6, 215-229.
102. Nusser, Z.; Sieghart, W.; Somogyi, P. Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J. Neurosci., 1998, 18, 1693-1703.
103. Akk, G.; Li, P.; Bracamontes, J.; Reichert, D.E.; Covey, D.F.; Steinbach, J.H. Mutations of the GABA-A receptor alpha1 subunit M1 domain reveal unexpected complexity for modulation by neuroactive steroids. Mol. Pharmacol., 2008, 74, 614-627.
104. Hosie, A.M.; Wilkins, M.E.; Smart, T.G. Neurosteroid binding sites on GABA(A) receptors. Pharmacol. Ther., 2007, 116, 7-19.
105. Akk, G.; Li, P.; Bracamontes, J.; Steinbach, J.H. Activation and modulation of concatemeric GABA-A receptors expressed in human embryonic kidney cells. Mol. Pharmacol., 2009, 75(6), 1400-1411
106. Hosie, A.M.; Clarke, L.; da Silva, H.; Smart, T.G. Conserved site for neurosteroid modulation of GABA A receptors. Neuropharmacology, 2009, 56, 149-154.
107. Rahman, M.; Lindblad, C.; Johansson, I.M.; Backstrom, T.; Wang, M.D. Neurosteroid modulation of recombinant rat alpha5beta2gamma2L and alpha1beta2gamma2L GABA(A) receptors in Xenopus oocyte. Eur. J. Pharmacol., 2006, 547, 37-44.
108. Belelli, D.; Lambert, J.J. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci., 2005, 6, 565-575.
109. Crawley, J.N.; Glowa, J.R.; Majewska, M.D.; Paul, S.M. Anxiolytic activity of an endogenous adrenal steroid. Brain Res., 1986, 398, 382-385.
110. Bitran, D.; Hilvers, R.J.; Kellogg, C.K. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res., 1991, 561, 157-161.
111. Steinbach, J.H.; Akk, G. Modulation of GABA(A) receptor channel gating by pentobarbital. J. Physiol., 2001, 537 (Pt 3), 715-733.
112. Meera, P.; Olsen, R.W.; Otis, T.S.; Wallner, M. Etomidate, propofol and the neurosteroid THDOC increase the GABA efficacy of recombinant alpha4beta3delta and alpha4beta3 GABA A receptors expressed in HEK cells. Neuropharmacology, 2009, 56, 155-160.